Hughes Melton

Hughes Melton is a Lebanon, Virginia, addiction specialist whose clinic and public-health work placed him at the center of Virginia’s effort to expand medication-assisted treatment. He sought to reach underserved patients, then helped shape a wider response that paired access to buprenorphine with counseling, care coordination, and tighter oversight. In a book attentive to the gaps between treatment and the criminal-justice system, Melton represents both the possibility of building care in rural communities and the labor required to make it reachable.

Identity and Background

Melton established his practice in Lebanon in 2000, motivated by a desire to treat people who were underserved. The narrative presents him as a younger rural counterpart to Art Van Zee: a physician working in a community where addiction care was scarce and where the distance between medical need and available services could be considerable.

His work extended beyond the clinic. By 2017, he had been tapped to help lead Virginia’s response to the crisis through the Virginia Department of Health. He and Sarah Melton, his wife, combined clinical work with policy and public education: Sarah was a pharmacy professor and statewide patient advocate, while Hughes helped direct the state response and worked with Medicaid officials on treatment access.

Highpower and Clinical Practice

Melton’s Suboxone clinic, Highpower, became a model for parts of the state’s treatment expansion. Sarah Melton described its approach as including strict urine-screening protocols as well as on-site group and individual counseling. The clinic’s practices stood in contrast to accounts from some patients of treatment settings where buprenorphine was overprescribed, diverted, or exchanged on the illicit market.

Patients at Highpower were among those who first explained buprenorphine diversion to the book’s author. Their accounts challenged harm-reduction proponents elsewhere who dismissed the practice when it was raised. The issue was not simply whether buprenorphine worked: it was also how prescribing, monitoring, and follow-up were organized, and whether patients could remain in treatment without the medication becoming another source of illicit supply.

The Meltons’ work was demanding enough that interviews often took place at night or in their cars. That detail accompanies a wider picture of a small clinical operation carrying responsibilities that reached well beyond routine appointments: patient care, education, advocacy, and the practical work of improving a fragmented system.

Expanding Access Across Virginia

Melton worked with state Medicaid officials to broaden reimbursement for treatment and to include payment for mandatory counseling and care coordination. The aim was partly to encourage cash-only clinics to accept insurance, including Medicaid, rather than leave patients to meet substantial out-of-pocket costs. In the book’s account, those costs and the limited availability of providers could turn treatment into a sequence of hurdles even for people ready to seek help.

At the time, federal rules limited MAT-certified doctors to treating 100 patients; the cap was raised to 275 later that year in response to the crisis. Virginia’s access to medication-assisted treatment would broaden considerably in 2017, in large part through Melton’s efforts, though the expansion reached communities slowly. The state’s Governor’s Access Plan offered additional addiction treatment and services to 14,000 Virginians, but only a fraction of those in need would benefit, and not until 2017. The distance between a policy announcement and a timely appointment remained a defining problem.

Melton’s state initiatives also included a statewide push for syringe exchange and tighter controls on MAT prescribing. Those measures reflected an effort to address both sides of the problem: barriers that kept people from treatment and practices that could undermine treatment’s safety or credibility.

Treatment, Risk, and Disagreement

The book does not present medication-assisted treatment as a simple or uncontested solution. Buprenorphine can prevent withdrawal and reduce cravings, yet its diversion and misuse generated deep opposition among some law-enforcement officials and drug-court judges. Sarah Melton argued that Suboxone’s naloxone component made it preferable to Subutex in settings where patients injected high doses of the latter; Subutex lacks that added blocker and was more sought after by some people who wanted to use other opioids as well.

The Meltons’ position was therefore not an uncomplicated defense of prescribing. Highpower’s screening and counseling requirements, alongside their concern about overprescribing, placed them within a debate over how to preserve access without treating maintenance medication as a perfect fix. The broader evidence discussed in the book also cautions that stopping treatment can carry substantial relapse risk. For Melton, expanding care and imposing safeguards were connected tasks rather than opposing aims.

Narrative Role and Significance

Melton’s story gives institutional scale to the book’s accounts of patients and families struggling to find care. A clinic in rural Lebanon, a physician helping direct a state response, and reimbursement rules negotiated with Medicaid officials all appear as parts of the same question: whether effective treatment can be made available before people are lost to waiting lists, cost, or gaps between services.

His role also complicates the familiar division between treatment and enforcement. The state response he helped shape included both expanded medication access and closer controls, while the book shows how criminal-justice and health-care systems can leave people navigating between them. Melton’s work offers a practical, local model—clinical treatment joined to counseling and public policy—without suggesting that a single clinic or policy change could meet the scale of need.